Pestalozzi advises Helix Acquisition Corp (HLXA), a Nasdaq-listed SPAC, in its business combination with MoonLake Immunotherapeutics AG
Helix Acquisition Corp (HLXA), a Nasdaq-listed special purpose acquisition company (SPAC) and MoonLake Immunotherapeutics AG, a Swiss based clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases agreed on a business combination.
At closing of the envisaged business combination, MoonLake will have access to approximately USD 230 Mio in cash (subject to redemptions), combining funds held in Helix’s trust account and the proceeds of a PIPE financing. The transaction – pursuing an Up-C structure – allows certain existing MoonLake shareholders to exchange their MoonLake shares against Helix shares on closing, while other existing MoonLake equity holders are granted the ability to exchange their MoonLake equity into Helix shares.
Pestalozzi advises Helix with regard to all Swiss law related aspects of the transaction and its implementation, which is expected for late 2021, early 2022.